Anaphylaxis with elevated serum tryptase after administration of intravenous ferumoxytol

NDT Plus

Volumn 3, Issue 4, 2010, Pages 341-342

  Santosh, Sadashiv ^a   Podaralla, Prashanth ^a   Miller, Brent ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

anaphylaxis; ferumoxytol; iron

Indexed keywords

FAMOTIDINE; FERAHEME; FERRIC HYDROXIDE SUCROSE; FERUMOXYTOL; IRON DEXTRAN; METHYLPREDNISOLONE; PREDNISONE; TRYPTASE; UNCLASSIFIED DRUG;

AGED; ANAPHYLAXIS; ANEMIA; ARTICLE; BACKACHE; BLOOD PRESSURE; CASE REPORT; CELL ACTIVATION; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DYSPNEA; FEMALE; HUMAN; HYPERTENSION; HYPOTENSION; MAST CELL; OXYGEN SATURATION; OXYGEN THERAPY; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; TONGUE SWELLING; TREATMENT RESPONSE; VOMITING; WHEEZING;

EID: 77956028834     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfq084     Document Type: Article

References (10)

1. Lu M, Cohen MH, Rieves D et al. FDA report: ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol 2010; 85: 315-319
2. Goetsch AT, Moore CV, Minnich V. Observations on the effects of massive doses of iron given intravenously to patients with hyperchromic anemia. Blood 1946; 1: 129-142
3. Auerbach M, Witt D, Toler W et al. Clinical use of the total dose intravenous infusion of iron dextran. J Lab Clin Med 1988; 111: 566-570
4. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet 2007; 369: 1502-1504
5. Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am 2006; 26: 451-463
6. Singh A, Patel T, Hertel J et al. Safety of ferumoxytol in patients with anemia and CKD. Am J Kidney Dis 2008; 52: 907-915
7. Provenzano R, Schiller B, Rao M et al. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 386-393
8. Spinowitz BS, Schwenk MH, Jacobs PM et al. The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients. Kidney Int 2005; 68: 1801-1807
9. Chertow GM, Mason PD, Vaage-Nilsen O et al. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21: 378-382
10. Coyne DW, Adkinson NF, Nissenson AR et al. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int 2003; 63: 217-224